ReviewJournal of cardiovascular translational research2013
Heart failure biomarkers.
Review in Journal of cardiovascular translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Shape dependency of gold nanorods through TMBRSC advances · 2023Article
- Non-invasive assessment of HFpEF in mouse models: current gaps and future directions.BMC medicine · 2022Article
- Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors.Sensors (Basel, Switzerland) · 2019Review
- Prediction of All-Cause Mortality Based on the Direct Measurement of Intrathoracic Impedance.Circulation. Heart failure · 2016Article
- Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients.Journal of cardiovascular translational research · 2015Article
- Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.European cardiology · 2015Review
- Guidelines for translational research in heart failure.Journal of cardiovascular translational research · 2015Article
- Biomarkers and heart disease: what is translational success?Journal of cardiovascular translational research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarker testing in patients with heart failure (HF) is rapidly expanding. With high-quality research indicating its diagnostic and prognostic capabilities, biomarkers are excellent adjuncts to manage patients with HF. Their superiority lies mainly in their reflection of ongoing pathophysiological events at a cellular level. Monitoring biomarker levels has been shown to provide incremental information on the progression of disease, thus allowing to better tailor treatment and management. Several biomarkers have gained attention in the past decade and continuing research demonstrates the specificity of each biomarker to be used on its own or in combination to improve diagnostic accuracy. This review will provide an insight into the role of such biomarkers, which are widely studied in the setting of HF so as to delineate their role in diagnosing, prognosticating, and titrating HF therapy.
Indexed as
Identifiers
23604646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.